Navigation Links
REMEDIAL II Trial of PLC's RenalGuard® Demonstrates Greater Efficacy than Current Standard of Care
Date:4/4/2011

FRANKLIN, Mass., April 4, 2011 /PRNewswire/ -- PLC Systems Inc. (OTCBB: PLCSF), a company focused on innovative medical device technologies, announced that final results from the REMEDIAL II investigator-sponsored clinical trial of RenalGuard® in Italy were presented today. The results showed that RenalGuard was much more effective than the current standard of care at preventing Contrast-Induced Nephropathy (CIN) and Dialysis in at-risk patients.

In scientifically significant results presented today at the American College of Cardiology Late Breaking Clinical Trial session of the annual conference (ACC.11), the investigators found that patients treated with RenalGuard and N-acetylcysteine (NAC) developed CIN, a serious and potentially fatal condition, at a much lower rate than patients in the control group who were treated with an infusion of sodium bicarbonate and NAC. Sodium bicarbonate plus NAC remains the current standard of care for the prevention of CIN in many catheterization labs worldwide.

Mark R. Tauscher, President and Chief Executive Officer of PLC Systems, said, "We are extremely pleased that the results of the REMEDIAL II clinical trial are consistent with findings from the MYTHOS trial presented in September 2010 at TCT, and provide additional scientific evidence that RenalGuard is safe and effective in combating CIN. This is another important proof point for RenalGuard and for PLC, and we're delighted that these results are being shared with practitioners and potential partners from around the world at ACC.11. We believe continued positive scientific findings like these will help us attract more interest from distributors, partners and customers for RenalGuard Therapy. I would particularly like to thank Dr. Briguori for his leadership in the field of CIN prevention and for utilizing PLC's RenalGuard in this trial."

Dr. Carlo Briguori, MD, PhD, Chief, Laboratory of Interventional Cardiology, Clinica Mediterranea, Naples
'/>"/>

SOURCE PLC Systems Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. REMEDIAL II Results on PLC Systems RenalGuard® to be Presented at ACC 2011s Late Breaking Clinical Trial Session
2. Data From Landmark Clinical Trial of Abbotts MitraClip® System Demonstrate Durable Clinical Benefits for Patients With Mitral Regurgitation Two Years After Treatment
3. New Subanalyses of the RE-LY Trial Showed Pradaxa Reduced Stroke Risk in Patients With Varying CHA2DS2-VASc Scores and Types of Non-Valvular Atrial Fibrillation
4. Publication in SLEEP Journal Demonstrates Positive Results of Large Multi-Center Clinical Trial for Provent® Sleep Apnea Therapy
5. Regado Biosciences, Inc. Presents Results of the RADAR Phase 2b Clinical Trial of its REG1 Anticoagulation System
6. Boston Scientific ION™ Platinum Chromium Stent System Demonstrates Strong Performance in Analysis of PERSEUS and TAXUS ATLAS Clinical Trial Data
7. Analysis of Data Across Multiple Drug Eluting Stent Trials Reinforces Positive Clinical Performance of XIENCE V®
8. Omeros Reports Outcome of Phase 3 Trials of OMS103HP
9. Conatus Pharmaceuticals Presents Results From a Phase 2 Clinical Trial of CTS-1027 in HCV Genotype 1 Null-Responders
10. FDA Approves Special Protocol Assessment for Phase 3 Trial of Polaris Groups Cancer Therapeutic, ADI-PEG 20, in the Treatment of Hepatocellular Carcinoma
11. Pharmasset Initiates Phase 2b ATOMIC Trial of PSI-7977 for Multiple HCV Genotypes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... YORK , Sept. 17, 2014  Levi & ... in connection with possible claims of breaches of fiduciary ... To get more information, click here: ... you. If you own common stock in ... please contact Eduard Korsinsky, Esq. either via ...
(Date:9/17/2014)... , Sept. 17, 2014 /PRNewswire-iReach/ -- ... white paper discussing improvements in the development ... structures for both normal and diseased tissue ... information, simplifies surgical procedures, lowers surgical costs ... surgical procedures. The clinical ...
(Date:9/17/2014)... , Sept. 17, 2014 Bronstein, Gewirtz & ... purchasers of the securities of PDL BioPharma, Inc. ("PDL ... -News).  Such investors are advised to contact Peretz ... Kimelman at info@bgandg.com or 212-697-6484. ... certain of its executives violated federal securities laws. ...
Breaking Medicine Technology:Patient Outcomes Improve When Molecular Chemical Imaging Technology Is Used to Aid Robotic Surgical Procedures, According to New White Paper 2Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Investigates claims on behalf of Investors of PDL BioPharma, Inc. --PDLI 2
(Date:9/17/2014)... 17, 2014 In its latest blog post, ... believes that having family close by during a stay in ... the process is successful, is highlighting a member of the ... the lives of addicts across the country and around the ... can reduce the blood pressure, heart rate, and stress levels ...
(Date:9/17/2014)... sound like the ideas of a science fiction ... an exciting new approach to imaging local and ... prostate cancer, scientists at Virginia Commonwealth University Massey ... Johns Hopkins Medical Institutions have provided proof-of-principle of ... doctors, ability to see tumors that have metastasized ...
(Date:9/17/2014)... NY (PRWEB) September 17, 2014 In ... acknowledges that “bi-weekly telephonic discovery conferences would be beneficial ... such conferences through mid-December. “At the end of December,” ... assess the need for additional conferences. , “The ... recognizes that there is still much to be discussed ...
(Date:9/17/2014)... Dennis Thompson HealthDay Reporter ... in the womb to household chemicals known as phthalates ... Columbia University researchers reported in a new study. ... developing asthma between age 5 and 11 if their ... two phthalates (pronounced thal-ates), the researchers found. The two ...
(Date:9/17/2014)... The Scripps Research Institute (TSRI) have devised a ... effective against vancomycin-resistant strains of MRSA and other ... to have not one but two distinct mechanisms ... evolve resistance quickly. , "This is the prototype ... in clinical use a generation or maybe even ...
Breaking Medicine News(10 mins):Health News:Latest Best Drug Rehabilitation Blog Post Highlights How Dogs are Helping Addicts Recover 2Health News:New non-invasive technique could revolutionize the imaging of metastatic cancer 2Health News:New non-invasive technique could revolutionize the imaging of metastatic cancer 3Health News:Transvaginal Mesh Lawsuit News: New Order in C.R. Bard MDL Sets Schedule of Conferences for September to December, the Rottenstein Law Group LLP Reports 2Health News:Prenatal Exposure to Chemicals in Plastics Linked to Asthma Risk in Kids 2Health News:Prenatal Exposure to Chemicals in Plastics Linked to Asthma Risk in Kids 3Health News:Prenatal Exposure to Chemicals in Plastics Linked to Asthma Risk in Kids 4Health News:Scripps Research Institute chemists modify antibiotic to vanquish resistant bacteria 2Health News:Scripps Research Institute chemists modify antibiotic to vanquish resistant bacteria 3
... tend to outlive males, a circumstance that is usually ... especially when they compete for females. This might also ... higher parasite burden than females. Therefore, high variability of ... be more important for males. Scientists at the Research ...
... tests should not be used to predict Alzheimer,s disease, the ... Although there is a link between the two, ... their sense of smell, and it may not necessarily mean ... "A nonspecific association between poor smell function and Alzheimer,s ...
... THURSDAY, May 10 (HealthDay News) -- A new weight-loss ... and Drug Administration showed promising results in a recent ... a combination of the drugs phentermine and topiramate, experienced ... health problems, the study found. The findings were reported ...
... privately insured colon cancer patients found that managed care presence ... surgery to treat colon cancer lowered costs, a national team ... University School of Public Health and Health Services reported in ... cancer is the second leading cause of cancer death in ...
... from systemic sclerosis, also known as scleroderma, than Caucasians. ... a journal of the American College of Rheumatology (ACR), ... likely to have antibodies that increased frequency and severity ... According to the ACR there are 49,000 ...
... Chronic exposure to cocaine reduces the expression of a ... in vivo research on the molecular basis of cocaine ... which produce greater sensitivity to the rewarding effects of ... for development of a treatment for cocaine addiction. It ...
Cached Medicine News:Health News:Living longer - variability in infection-fighting genes can be a boon for male survival 2Health News:Smell Tests Don't Predict Alzheimer's, Study Finds 2Health News:New Weight-Loss Drug Shows Promise in Trial 2Health News:New Weight-Loss Drug Shows Promise in Trial 3Health News:Economic theory actually works in health care 2Health News:Systemic sclerosis complications more severe in African Americans than Caucasians 2Health News:Chronic cocaine use triggers changes in brain's neuron structure 2
The Eppendorf Maxipettor is a continuously adjustable pipette for precise pipetting of volumes up to 10 ml (in 10 l increments). Even liquids with a high vapor pressure or viscosity can be pipetted w...
... The Repeater Plus, a handheld manual ... saving time on long series pipetting. Its ... exceptional support for research tasks, and its ... with repetitive work. The nine Combitips allow ...
eValuator fixed-curve diagnostic electrophysiology catheters offer an effective balance between clinical performance and cost....
The True Non-Compliant Balloon....
Medicine Products: